Polaryx Therapeutics, Inc
Polaryx Therapeutics, Inc is a biotechnology company focused on healthcare diagnostics, developing and commercializing diagnostic solutions for disease detection and monitoring.
Business. Polaryx Therapeutics, Inc. (PLYX.O) is a biotechnology and medical research company operating within the healthcare diagnostics sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. As segment and geographic breakdowns are not specified, the company is described at the industry level as a participant in pharmaceuticals and medical research.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Polaryx Therapeutics, Inc. (PLYX.O) is a biotechnology and medical research company operating within the healthcare diagnostics sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. As segment and geographic breakdowns are not specified, the company is described at the industry level as a participant in pharmaceuticals and medical research.
Polaryx Therapeutics has a market capitalization of $161.44 million, with a current market price of $3.41 per share, and no dilution risk based on the current share count of 47.34 million shares outstanding, both basic and diluted. The company has not disclosed balance-sheet data, and as a result, liquidity risk cannot be assessed.
The company's profitability and return metrics are not available in the current dataset, and no direct comparison to industry peers can be made at this time. However, the mean price target from analysts is $10.00, indicating a potential upside of 193.55% from the current market price.
Polaryx's revenue concentration and geographic exposure are not disclosed in the available data, and no segment-specific financials are provided. The company's business is centered on healthcare diagnostics, but the extent of geographic diversification or segment-specific performance is not available for analysis.
The company's growth trajectory is not quantified in the current dataset, but the analyst price targets suggest a strong positive outlook. No revenue history is available to assess historical growth rates.
The company is flagged for liquidity risk due to the absence of balance-sheet data and no going-concern language in the source documents. However, dilution risk is currently assessed as low, with no evidence of recent or planned share issuances.
No recent filings or transcripts are available in the dataset to provide insight into management commentary, strategic shifts, or operational updates. The company's narrative is based on the current financial snapshot and analyst estimates.
- Analysts have assigned a mean price target of $10.00, suggesting a potential 193.55% upside from the current market price.
- The company has no dilution risk based on the current share count, with basic and diluted shares outstanding being equal.
- Liquidity risk cannot be assessed due to the absence of balance-sheet data and no going-concern language in the source documents.
- No segment or geographic revenue breakdown is available, limiting the ability to assess diversification or concentration risk.
- The company's profitability and return metrics are not disclosed, making it difficult to compare with industry peers.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Polaryx Therapeutics, Inc Market data — financials · 2026-05-29
- Polaryx Therapeutics, Inc Market data — analyst estimates · 2026-05-29
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Leadership
- Alex Keun Mo YangChairman of the Board, Chief Executive Officer
Insider activity
- Director, Chief Executive Officer, 10% owner · Common StockBought 88 453 @ $4,07$360K · 2026-05-27
- Director, Chief Financial Officer · Common StockBought 2 867 @ $2,79$8K · 2026-02-18
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Return on equity (FY 2025-12-31): -196.8%Derived (calculated)
- Return on assets (FY 2025-12-31): -173.8%Derived (calculated)
- Current ratio (FY 2025-12-31): 8.55xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.13xDerived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 11.3%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 77.5%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 77.5%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 70.4%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -53.3%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -79.7%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): 122.9%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -3.1%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 3.4%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 109.3%Derived (calculated)
- Operating cash flow (annual): USD -3.94MSEC XBRL filing
- Shares outstanding (annual): 47.34MSEC XBRL filing
- Pre-tax income (annual): USD -8.98MSEC XBRL filing
- Total operating expenses (annual): USD 7.82MSEC XBRL filing
- Net income (annual): USD -8.98MSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES -0SEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES -0SEC XBRL filing
- Current liabilities (annual): USD 605KSEC XBRL filing
- Total liabilities (annual): USD 605KSEC XBRL filing
- Cash & equivalents (annual): USD 5.14MSEC XBRL filing